RTP Mobile Logo
Oncology Today with Dr Neil Love: Current and Future Management of Follicular Lymphoma (Video Interview)
Released July 2022

Featuring an interview with Dr Loretta Nastoupil. Published July 5, 2022. (Video Interview)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of follicular lymphoma.


    • Evaluate published research data and clinical investigator perspectives when designing an optimal induction therapeutic approach for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
    • Identify patient- and disease-specific factors that may portend poor response to initial chemoimmunotherapy, and consider this information as part of treatment decision-making for individuals with previously untreated FL.
    • Appreciate available data with rituximab/lenalidomide for patients with treatment-naïve and relapsed/refractory (R/R) FL, and optimally incorporate this regimen into management algorithms.
    • Recognize the recent FDA approval of tazemetostat for R/R FL, and identify patients for whom treatment with this novel agent may be appropriate.
    • Recall key efficacy and safety data from clinical trials of approved and investigational chimeric antigen receptor T-cell therapies directed at CD19 for R/R FL, and identify patients who may be candidates for this approach.
    • Assess ongoing clinical trials evaluating other novel investigational approaches for newly diagnosed or R/R FL, and obtain consent from appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentations Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Loretta J Nastoupil, MD
    Associate Professor
    Section Chief, Indolent Lymphoma
    Section Chief, New Drug Development
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Janssen Biotech Inc, MEI Pharma Inc, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, IGM Biosciences Inc, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

    Release date: July 2022
    Expiration date: July 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):